application's abstract): The HACTU is part of the HIV clinical research arm of the University of Hawaii's program in Retrovirology. The HACTU has been a formal unit of the AACTG since 1990 with funding received under a minority institution initiative. The site brings to the AACTG: (1) an established clinical trials unit within the AACTG with a record in clinical trial management, currently meeting all ACTG standards for site operations; (2) access to Hawaii's ethnically diverse population, having previously contributed 41 percent of all ACTG's enrollees of Asian/Pacific Islander descent; (3) a unit with wide community, state governmental and university support for its operations as the only HIV/AIDS clinical research program in Hawaii; (4) a continued commitment to participate as broadly as feasible not only in AACTG's main antiretroviral trials but also in specialized areas of HIV immunology and complication research targeted at areas of special importance by the AACTG leadership; and (5) a minority unit with a record of increasing scientific contributions to the ACTG over the past five years and a commitment to contribute to the AACTG's scientific agenda in the next five years. The areas of pathogenesis/treatment of HIV/Hepatitis B and C co-infection; HIV-associated interest include metabolic complications; role of insertional mutagenesis and macrophages in the pathogenesis of HIV- associated malignancies; central nervous system (CNS) disease; and the impact of menopause and female replacement hormonal therapy on HIV-1 activity.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AI034853-10
Application #
6488952
Study Section
Special Emphasis Panel (ZAI1-PSS-A (S1))
Program Officer
Matula, Margaret A
Project Start
1996-01-01
Project End
2004-12-31
Budget Start
2002-01-01
Budget End
2002-12-31
Support Year
10
Fiscal Year
2002
Total Cost
$1,367,841
Indirect Cost
Name
University of Hawaii
Department
Type
Schools of Medicine
DUNS #
121911077
City
Honolulu
State
HI
Country
United States
Zip Code
96822
Martin, Maureen P; Naranbhai, Vivek; Shea, Patrick R et al. (2018) Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. J Clin Invest 128:1903-1912
Haas, David W; Bradford, Yuki; Verma, Anurag et al. (2018) Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events. Pharmacogenet Genomics 28:179-187
Venuto, Charles S; Lim, Jihoon; Messing, Susan et al. (2018) Inflammation investigated as a source of pharmacokinetic variability of atazanavir in AIDS Clinical Trials Group protocol A5224s. Antivir Ther 23:345-351
Li, Binglan; Verma, Shefali S; Veturi, Yogasudha C et al. (2018) Evaluation of PrediXcan for prioritizing GWAS associations and predicting gene expression. Pac Symp Biocomput 23:448-459
Gupta, Samir K; Yeh, Eunice; Kitch, Douglas W et al. (2017) Bone mineral density reductions after tenofovir disoproxil fumarate initiation and changes in phosphaturia: a secondary analysis of ACTG A5224s. J Antimicrob Chemother 72:2042-2048
Verma, Anurag; Bradford, Yuki; Verma, Shefali S et al. (2017) Multiphenotype association study of patients randomized to initiate antiretroviral regimens in AIDS Clinical Trials Group protocol A5202. Pharmacogenet Genomics 27:101-111
Bednasz, Cindy J; Venuto, Charles S; Ma, Qing et al. (2017) Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants. Ther Drug Monit 39:596-603
Verma, Shefali S; Frase, Alex T; Verma, Anurag et al. (2016) PHENOME-WIDE INTERACTION STUDY (PheWIS) IN AIDS CLINICAL TRIALS GROUP DATA (ACTG). Pac Symp Biocomput 21:57-68
Moore, Carrie B; Verma, Anurag; Pendergrass, Sarah et al. (2015) Phenome-wide Association Study Relating Pretreatment Laboratory Parameters With Human Genetic Variants in AIDS Clinical Trials Group Protocols. Open Forum Infect Dis 2:ofu113
Lehmann, David S; Ribaudo, Heather J; Daar, Eric S et al. (2015) Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols. Pharmacogenet Genomics 25:51-9

Showing the most recent 10 out of 114 publications